Cantargia
Develops antibody therapies targeting IL1RAP for cancer and inflammatory diseases.
CANTA | ST
Overview
Corporate Details
- ISIN(s):
- SE0006371126 (+3 more)
- LEI:
- 549300GKWRT7RXI4VS85
- Country:
- Sweden
- Address:
- Scheelevägen 27, 223 63 Lund
- Website:
- https://cantargia.com/en/
- Sector:
- Manufacturing
Description
Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-02-20 16:10 |
Cantargia reports US regulatory approval to start pancreatic cancer phase IIb t…
|
English | 84.1 KB | ||
| 2024-02-20 16:10 |
Cantargia meddelar regulatoriskt godkännande i USA för att starta fas IIb-studi…
|
Swedish | 85.2 KB | ||
| 2024-02-12 17:15 |
Cantargia presenterar nya kliniska data som stärker nadunolimabs potential vid …
|
Swedish | 87.1 KB | ||
| 2024-02-12 17:15 |
Cantargia reports new data reinforcing nadunolimab as cancer combination therapy
|
English | 86.0 KB | ||
| 2024-01-09 17:30 |
Cantargia reports phase I clinical progress in the CAN10 project
|
English | 82.1 KB | ||
| 2024-01-09 17:30 |
Cantargia rapporterar kliniska framsteg i fas I studien för CAN10-projektet
|
Swedish | 82.6 KB | ||
| 2023-12-01 13:09 | Swedish | 36.1 KB | |||
| 2023-11-30 13:00 |
Nytt antal aktier och röster i Cantargia
|
Swedish | 76.2 KB | ||
| 2023-11-30 13:00 |
New number of shares and votes in Cantargia
|
English | 76.2 KB | ||
| 2023-11-20 09:10 |
Third party withdraws appeal related to Cantargia patent
|
English | 83.7 KB | ||
| 2023-11-20 09:10 |
Tredje part drar tillbaka överklagande relaterat till Cantargias patent
|
Swedish | 84.6 KB | ||
| 2023-11-10 07:00 | Swedish | 832.5 KB | |||
| 2023-11-10 07:00 | English | 822.5 KB | |||
| 2023-11-03 09:00 |
Nomination Committee appointed ahead of 2024 Annual General Meeting
|
English | 76.1 KB | ||
| 2023-11-03 09:00 |
Valberedning utsedd inför årsstämman 2024
|
Swedish | 76.1 KB |
Automate Your Workflow. Get a real-time feed of all Cantargia filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cantargia
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cantargia via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-19 | Nedjad Losic | Other | Buy | 21,375 | 33,131.25 SEK |
| 2025-01-02 | Antonius Franciscus Berkien | Other | Other | 21,621 | 39,998.85 SEK |
| 2024-12-20 | Göran Forsberg | Other | Other | 152,206 | 281,581.10 SEK |
| 2024-12-20 | Nedjad Losic | Other | Other | 12,875 | 23,818.75 SEK |
| 2024-12-09 | Antonius Franciscus Berkien | Other | Buy | 3,741 | 6,733.80 SEK |
| 2023-01-19 | Nedjad Losic | Other | Buy | 3,918 | 29,110.74 SEK |
| 2023-01-17 | Göran Forsberg | Other | Buy | 17,000 | 140,250.00 SEK |
| 2023-01-17 | Bengt Jöndell | Other | Buy | 6,500 | 54,665.00 SEK |
| 2022-07-28 | Göran Forsberg | Other | Other | 91,765 | 344,118.75 SEK |
| 2022-07-28 | Thoas Fioretos | Other | Other | 78,400 | 294,000.00 SEK |
Peer Companies
